BERWYN, Pa.–(BUSINESS WIRE)–Amring Pharmaceuticals Inc. (Amring), filial de Nordic Group B.V. (Nordic Pharma), anuncia el nombramiento del Dr. Jai G. Parekh como director comercial para el cuidado ocular en EE. UU. Nordic Pharma ha expandido reciente…
Category: Business
Nordic Group B.V. Through Its Subsidiary Amring Pharmaceuticals Inc., Announces Jai G. Parekh, MD, MBA as Chief Commercial Officer, Eye Care U.S.
BERWYN, Pa.–(BUSINESS WIRE)–Amring, a subsidiary of Nordic Group B.V. (Nordic Pharma), announces Jai G. Parekh, MD, MBA as Chief Commercial Officer, Eye Care U.S.
Alcon Announces Positive Topline Results From Phase 3 COMET Trials of AR-15512, a Novel Topical Drug Candidate for Dry Eye
GENEVA–(BUSINESS WIRE)–Alcon Announces Positive Topline Results From Phase 3 COMET Trials of AR-15512, a Novel Topical Drug Candidate for Dry Eye
Alcon Announces Positive Topline Results From Phase 3 COMET Trials of AR-15512, a Novel Topical Drug Candidate for Dry Eye
GENEVA–(BUSINESS WIRE)–Alcon Announces Positive Topline Results From Phase 3 COMET Trials of AR-15512, a Novel Topical Drug Candidate for Dry Eye
Aviceda Announces First Patient Enrolled in Phase 2 GLYCO Clinical Trial Evaluating AVD-104 for the Treatment of Diabetic Macular Edema
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aviceda Therapeutics, a private clinical-stage biotech company focused on developing next-generation immunomodulators by harnessing the power of glycobiology to alleviate chronic, non-resolving inflammation, announced…
Zenni Optical Eyes Blazing Fast Search with Algolia
SAN FRANCISCO–(BUSINESS WIRE)–Zenni sees 34% increase in revenue with Algolia.
Aldeyra Therapeutics Provides Clinical and Regulatory Update and Announces Advancement of RASP Platform in Systemic and Retinal Inflammatory Diseases
LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced advancement of its RA…
LumiThera geeft update over FDA-beoordeling van Valeda-behandeling voor patiënten met droge AMD
SEATTLE–(BUSINESS WIRE)–LumiThera Inc., een bedrijf gespecialiseerd in medische apparatuur dat PBM-behandeling (fotobiomodulatie) aanbiedt voor oogschade en oogaandoeningen, maakte vandaag een update bekend over de wettelijke status van het Valeda® L…
LumiThera gibt aktuellen Stand der FDA-Prüfung der Valeda-Behandlung für Patienten mit trockener AMD bekannt
SEATTLE–(BUSINESS WIRE)–LumiThera Inc., ein Medizintechnikunternehmen, das Photobiomodulation (PBM) zur Behandlung von Augenschäden und -erkrankungen anbietet, gab heute ein Update zum Zulassungsstatus des Valeda® Light Delivery System bekannt. Nach …
LumiThera offre un aggiornamento sulla valutazione da parte dell'FDA del trattamento Valeda per i pazienti affetti da degenerazione maculare senile (DMS)
SEATTLE–(BUSINESS WIRE)–LumiThera Inc., azienda di dispositivi medici che offre trattamenti di fotobiomodulazione (PBM) per danni e malattie oculari, ha annunciato oggi un aggiornamento sullo stato normativo del Valeda® Light Delivery System. A segui…
LumiThera fait une mise à jour de l'examen sur le traitement du Valeda par la FDA pour les patients atteints de DMLA sèche
SEATTLE–(BUSINESS WIRE)–LumiThera Inc. est une entreprise de dispositifs médicaux qui propose un traitement des lésions et des maladies oculaires par photobiomodulation (PBM) a annoncé aujourd’hui une mise à jour du statut réglementaire du système de…
Alcon to Present at 2024 Annual J.P. Morgan Healthcare Conference
GENEVA–(BUSINESS WIRE)–Alcon to Present at 2024 Annual J.P. Morgan Healthcare Conference
Alcon to Present at 2024 Annual J.P. Morgan Healthcare Conference
GENEVA–(BUSINESS WIRE)–Alcon to Present at 2024 Annual J.P. Morgan Healthcare Conference
Aldeyra Therapeutics Announces Statistically and Clinically Significant Improvement from Baseline in Phase 2 Clinical Trial of ADX‑629 in Patients with Atopic Dermatitis
LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced positive top-line res…
EyeSouth Partners Affiliates With Atlantic Eye Institute, Representing The Network’s 39th Affiliation and Ninth in Florida
ATLANTA–(BUSINESS WIRE)–EyeSouth Partners (“EyeSouth” or the “Company”) is excited to announce that it has partnered with Atlantic Eye Institute, representing its ninth affiliation in Florida and 39th affiliation overall. EyeSouth is an eye care-focu…
Riassunto: Nordic Pharma Group B.V. completa, tramite la propria affiliata Amring Pharmaceuticals Inc., l’acquisizione di Visant Medical finalizzata al lancio di un’innovativa terapia della sindrome dell’occhio secco negli Stati Uniti
BERWYN, Pennsylvania–(BUSINESS WIRE)–Amring Pharmaceuticals Inc. (Amring), un’affiliata di Nordic Group B.V. (Nordic Pharma), oggi ha annunciato di avere completato l’acquisizione di Visant Medical, Inc. (Visant), un leader nell’innovazione medico-te…
Resumen: Nordic Pharma Group B.V., con su filial Amring Pharmaceuticals Inc., cierra la adquisición de Visant Medical para presentar un tratamiento novedoso contra la sequedad ocular en Estados Unidos
BERWYN, Pensilvania–(BUSINESS WIRE)–Amring Pharmaceuticals Inc. (Amring), filial de Nordic Group B.V. (Nordic Pharma), ha anunciado hoy que se ha concretado la adquisición de Visant Medical, Inc. (Visant), líder en innovación de tecnología médica par…
Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from Phase 2 Clinical Trial of ADX-629 in Patients with Atopic Dermatitis
LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced it will host a webcast and conference call on Tuesday, December 19, 2023, at 8:00 a.m. (ET) to provide top-line results from a Phase 2 clinical trial…
Samenvatting: Nordic Pharma Group B.V. rondt via haar dochteronderneming Amring Pharmaceuticals Inc. de overname af van Visant Medical en lanceert een nieuwe therapie voor droge-ogenziekte in de Verenigde Staten
BERWYN, Pa.–(BUSINESS WIRE)–Amring Pharmaceuticals Inc. (Amring), een dochteronderneming van Nordic Group B.V. (Nordic Pharma), kondigde vandaag aan dat de overname van Visant Medical, Inc. (Visant) is afgerond. Visant Medical is een toonaangevend be…
Nordic Pharma Group B.V. schließt über ihre Tochtergesellschaft Amring Pharmaceuticals Inc. die Übernahme von Visant Medical ab, um in den Vereinigten Staaten eine neuartige Therapie für trockene Augen einzuführen
BERWYN, Pennsylvania–(BUSINESS WIRE)–Amring Pharmaceuticals Inc. (Amring), eine Tochtergesellschaft der Nordic Group B.V. (Nordic Pharma), gab heute den Abschluss der Übernahme von Visant Medical, Inc. (Visant) bekannt, einem Marktführer im Bereich d…